Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17660854 | 1.00 | PIK3CD (0.52) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL14770070 | 0.89 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL356503 | 0.86 | PIK3CD (0.59) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL356449 | 0.86 | PIK3CD (0.59) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL29422878 | 0.86 | PIK3CD (0.59) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL18806913 | 0.86 | PIK3CB (0.68) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL356882 | 0.84 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL13227925 | 0.82 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL12871709 | 0.82 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA | |
| SCHEMBL14999618 | 0.79 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CGPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9974792-B2 | Methods for treating cancers | GILEAD SCIENCES, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9968601-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9931338-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170258804-A1 | METHODS FOR TREATING CANCERS | Kronos Bio, Inc. | 2017-09-14 | — | — | US | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170035755-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-9504684-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | PIK3CD 726/4885PIK3CB 546/4885PIK3CG 949/4885 |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LCK, LYN | PIK3CD 333/4885PIK3CB 378/4885PIK3CG 358/4885 |
| US-20170035755-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CD 236/4885PIK3CB 383/4885PIK3CG 297/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | PIK3CD 726/4885PIK3CB 546/4885PIK3CG 949/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | PIK3CD 726/4885PIK3CB 546/4885PIK3CG 949/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | PIK3CD 726/4885PIK3CB 546/4885PIK3CG 949/4885 |
| US-20170258804-A1 | METHODS FOR TREATING CANCERS | MCL1, BCL9, CD44 | PIK3CD 4650/4885PIK3CB 4298/4885PIK3CG 4474/4885 |
| US-20160310490-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CD 188/4885PIK3CB 250/4885PIK3CG 282/4885 |
| US-20160058758-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CD 236/4885PIK3CB 383/4885PIK3CG 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.